1. Lantheus Holdings (NASDAQ:LNTH)
Average Upside Potential: 34.53%
Forward Price-to-Earnings Ratio: 1.45
Number of Hedge Fund Holders: 34
Lantheus Holdings (NASDAQ:LNTH) is a global leader in the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Its products are used to help healthcare professionals diagnose and monitor a variety of diseases, including cancer, heart disease, and brain disorders. It’s focused on developing innovative products and expanding its global reach.
Since the beginning of 2024, the company’s products have positively impacted over 3.4 million patients and their families. It’s expanding its pipeline with late and early-stage assets, including NAV-4694, a next-generation F18 PET imaging agent candidate targeting Alzheimer’s disease. It also acquired MK-6240, another Alzheimer’s disease diagnostic candidate.
The company acquired the global rights to Life Molecular Imaging’s RM2 clinical-stage radio diagnostic and radiotherapeutic pair, targeting the gastrin-releasing peptide receptor. It’s overexpressed in prostate cancer cells, making RM2 a potential diagnostic tool for earlier stages of the disease. Management plans to initiate a Phase I/IIa prostate cancer study with Life Molecular.
It also licensed two product candidates from Radiopharm Theranostics, including an LRRC15-targeted monoclonal antibody and a TROP2-targeted nanobody radioconjugate. These candidates have potential applications in various cancers.
Revenue made in Q2 2024 was $349.09 million, up 22.50% year-over-year. PYLARIFY sales grew 30%, driven by increased awareness and adoption. PYLARIFY is the leading PSMA PET imaging agent. DEFINITY sales increased 11%, driven by its clinical and commercial value proposition.
Lantheus Holdings (NASDAQ:LNTH) is committed to advancing innovation and delivering better patient outcomes, making it a great investment opportunity.
ClearBridge Small Cap Value Strategy stated the following regarding Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q2 2024 investor letter:
“Health care results lifted relative performance during the period and included our top two individual performers in Lantheus and newer portfolio addition Corcept Therapeutics. Lantheus Holdings, Inc. (NASDAQ:LNTH), which makes diagnostic and therapeutic products that help clinicians diagnose and treat heart, cancer and other diseases, saw its share price rise on strong first-quarter results.”
While we acknowledge the growth potential of Lantheus Holdings (NASDAQ:LNTH), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LNTH but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
